It has been shown that S1P3 is a target of Fingolimod, a synthetic analog of S1P, which is approved as an oral treatment for relapsing-remitting multiple sclerosis [56]. The gene discussed is MBTPS1; the disease is relapsing-remitting multiple sclerosis.